

Test	Sensitivity	Specificity	Population studied
Antibody tests			
EIA (IgM & IgG) antibody ⁷⁻⁹	59%–88%	68%–96% (Cross reacts with other dimorphic fungi)	General patient population, immunocompromised population, patients with disseminated disease
Complement fixation (CF) antibody ^{7,10,11}	65%–83%	High	General patient population, immunocompromised population, patients with disseminated disease
Immunodiffusion (ID) antibody ⁷	60%	99%	General patient population, immunocompromised population, patients with disseminated disease
Lateral flow assay (LFA) antibody ¹²	31%	92%	General patient population
Antigen tests			
EIA urine antigen ^{15,16}	37%–71%	High (but does cross-react with other dimorphic fungi)	General patient population, immunocompromised population, patients with disseminated disease
EIA serum antigen ^{16,17}	51%–73%	High (but does cross-react with other dimorphic fungi)	General patient population, immunocompromised population, patients with disseminated disease
Other tests			
Histopathology ⁵	23%–84%	High	General patient population, patients with diabetes, patients with disseminated disease
Cytology ⁵	15%–75%	High	General patient population, patients with diabetes, patients with disseminated disease
PCR ^{13,14}	56%–75%	99%–100%	General patient population